Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (8496)	1/26/1999 6:44:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

Bluegreen, I was pleased with todays news, but I will get much more excited when we hear about the first license for the humanization technology! " BERKELEY, CA -- June 15, 1998 -- XOMA Corporation (Nasdaq: XOMA) ) announced that the US Patent Office will issue to XOMA a patent broadly covering a new method for humanizing monoclonal antibodies. This human engineering (HE) technique represents a novel alternative to the complementarity-determining region (CDR) grafting methods in widespread use today. "XOMA's technology is a straightforward humanization method that obviates the need for methods based on CDR-grafting," said Jack Castello, chairman, president and CEO of XOMA. "Our method has already been used for our targeted immunofusion (TIF) program. We plan to offer the HE method to companies seeking to license an easy and effective humanization technology." Who will be the first and when?